Zapping tumors and boosting immunity: new hope for pancreatic cancer patients
NCT ID NCT06378047
Summary
This early-stage study tested whether combining two treatments is safe for people with advanced pancreatic cancer that hasn't spread. First, doctors used electricity to destroy tumor cells (irreversible electroporation), then gave an immunotherapy drug (pembrolizumab) to help the immune system fight any remaining cancer. The goal was to see if this combination approach is tolerable after patients already received standard chemotherapy and radiation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.